BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc. – An emergency aid or treatment given to an individual who is injured or affected with a sudden illness, before the arrival of regular medical services can be termed as first aid.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Epilepsy is a chronic neurological disorder that can cause unfounded and ongoing seizures.

Wilmington, Delaware, United States, Transparency Market Research Inc. – The demand in the global bioimpendance analysers market is surging owing to high growth potential amongst emerging economies such as Brazil and India.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Experiments in the field of biology includes the use of drugs or gene editing or implants which improve the capabilities or qualities of living organisms.

Wilmington, Delaware, United States, Transparency Market Research Inc. – In the last few years, the manufacturers have created novel aesthetic gadgets, resulting in a rise in demand for aesthetic treatments.

Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company, announced its results for the first half-year ended June 30, 2022.

J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGFR TKI ‘JIN-A02' was presented on the 8th of August, at the 2022 IASLC World Conference on Lung Cancer held in Vienna, Austria, during the official session entitled “Overcoming Resistance to EGFR Inhibitors”.

Amsterdam, the Netherlands - Royal Philips, a global leader in health technology, announced that Roy Jakobs is proposed to succeed Frans van Houten as President and Chief Executive Officer, effective October 15, 2022.

OKYO Pharma Limited is pleased to announce its final audited results for the year ended 31 March 2022.

Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company has developed a Peptide Docking Vehicle to achieve a peptide-enhanced GalNAc platform for siRNA drug delivery.